$NEUPJun 26, 2026, 8:15 PMAI processed
Neuphoria confirms talks with Scancell on potential acquisition; Scancell would seek Nasdaq listing
AI Summary
Neuphoria (NEUP) confirmed it is in discussions with London-listed Scancell about a possible acquisition/combination and said Scancell would become Nasdaq-listed if a transaction closes, but emphasized there is no certainty a deal will be reached. The company reminded investors that its lead asset BNC210 missed primary and secondary endpoints in the AFFIRM-1 Phase 3 trial and development was halted, and said it is conducting a strategic review.
Positives
- Company publicly confirms discussions with Scancell about a potential acquisition/combination
- Scancell would become a Nasdaq-listed company if a transaction closes
- Confirmation clarifies prior market speculation and sets expectation for future SEC/Nasdaq-compliant announcements
Negatives
- No certainty any agreement will be reached, terms are unknown
- BNC210 missed primary and secondary endpoints in the AFFIRM-1 Phase 3 trial (announced Oct 20, 2025)
- Development of BNC210 in social anxiety disorder has been halted and the company is under a strategic review